Last reviewed 2026-04-20 · How we verify

Buspar (BUSPIRONE)

Buspar (BUSPIRONE) is a small molecule drug developed by Mead Johnson and currently owned by Bristol Myers Squibb. It targets the D(2) dopamine receptor and is classified as a buspirone, which is a non-benzodiazepine anxiolytic. Buspar is FDA-approved for the treatment of generalized anxiety disorder and is available as a generic medication. The commercial status of Buspar is off-patent, with 19 generic manufacturers available. Key safety considerations include its low bioavailability of 4%.

At a glance

Approved indications

• Generalized anxiety disorder

Common side effects

• Dizziness
• Drowsiness
• Nausea
• Dry mouth
• Fatigue
• Headache
• Insomnia
• Tachycardia/Palpitations
• Nervousness
• Abdominal/gastric distress
• Constipation
• Diarrhea

Drug interactions

• Ioflupane I-123
• diltiazem
• erythromycin
• itraconazole
• linezolid
• nefazodone
• phenelzine
• rasagiline
• rifabutin
• rifampicin
• rifapentine

Key clinical trials

• Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment (PHASE4)
• Transformation of Paralysis to Stepping (EARLY_PHASE1)
• Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury (PHASE2)
• Buspirone for Anxiety in Autistic Youth (PHASE4)
• Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression (PHASE4)
• Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal (NA)
• Spinal Cord Neuromodulation for Spinal Cord Injury (PHASE1,PHASE2)
• Evaluating Buspirone to Treat Opioid Withdrawal (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.